Cullinan Therapeutics (CGEM) Income towards Parent Company: 2021-2023
Historic Income towards Parent Company for Cullinan Therapeutics (CGEM) over the last 3 years, with Dec 2023 value amounting to -$25.6 million.
- Cullinan Therapeutics' Income towards Parent Company rose 5.56% to -$25.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$155.1 million, marking a year-over-year decrease of 241.97%. This contributed to the annual value of -$167.6 million for FY2024, which is 8.04% down from last year.
- As of Q4 2023, Cullinan Therapeutics' Income towards Parent Company stood at -$25.6 million, which was up 34.76% from -$39.2 million recorded in Q3 2023.
- Over the past 5 years, Cullinan Therapeutics' Income towards Parent Company peaked at $174.1 million during Q2 2022, and registered a low of -$58.1 million during Q1 2023.
- Its 3-year average for Income towards Parent Company is -$9.4 million, with a median of -$25.2 million in 2022.
- Data for Cullinan Therapeutics' Income towards Parent Company shows a peak YoY increase of 1,158.85% (in 2022) and a maximum YoY decrease of 1,006.27% (in 2022) over the last 5 years.
- Cullinan Therapeutics' Income towards Parent Company (Quarterly) stood at -$34.2 million in 2021, then grew by 20.87% to -$27.1 million in 2022, then grew by 5.56% to -$25.6 million in 2023.
- Its Income towards Parent Company was -$25.6 million in Q4 2023, compared to -$39.2 million in Q3 2023 and -$32.2 million in Q2 2023.